SeminarRespiratory syncytial virus infection
Section snippets
Epidemiology
RSV causes a substantial amount of illness in young infants and elderly people. It is a seasonal virus, with peak rates of infection occurring annually in the cold season in temperate climates, and in the rainy season, as temperatures fall, in tropical climates. It affects about 90% of infants and young children by the age of 2 years; peak rates occur in infants aged 6 weeks to 6 months, but particularly in those under 3 months of age. Infection rates in Houston, USA, were 68·8 per 100
RSV and the immune response to infection
The RSV genome comprises a single strand of negative-sense RNA, 15 222 nucleotides in length,14 which yields ten major proteins. The F (fusion) and G (attachment) glycoproteins are the major surface antigenic determinants. Other proteins are primarily structural: the small hydrophobic proteins, matrix proteins, and the 22 kDa protein are associated with the viral envelope, and the nucleoprotein, phosphoprotein, and large nucleoprotein are found in the nuclear capsule. The function and
Clinical manifestations and diagnosis
The most common infection caused by RSV is of the upper respiratory tract; such infections are characterised by rhinitis, cough, and sometimes fever. Acute otitis media occurs in up to a third of children with RSV illness; both RSV and bacterial pathogens have been isolated from the middle ears of children with RSV. Croup also occurs with RSV infection, but bronchiolitis and pneumonia are the commonest manifestations in children. Signs of upper-respiratory-tract involvement commonly precede
Management
Infection of the lower respiratory tract with RSV is a self-limited condition in most cases. In normal infants with RSV lower-respiratory-tract infection, the inflammatory response has a greater effect on severity than does viral replication, and there is no unequivocal evidence to suggest that any antiviral or anti-inflammatory agents (alone or in combination) can reduce the length of RSV-related hospital stays in normal infants and young children. There is, therefore, much variation in the
Prevention
A vaccine for RSV is needed, and a protective live, attenuated vaccine administered at or around birth would be ideal. However, problems such as insufficient attenuation of the vaccine strain of RSV,42 its thermolability, and the need to include A and B strains in each vaccine have hindered trials in infants under 3 months of age. Furthermore, since repeated infections with RSV occur in children, any vaccine will need to be more immunogenic than wild-type RSV itself. Several vaccine strains42,
References (52)
- et al.
Pediatric Investigation Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial virus lower respiratory tract infection
J Pediatr
(1996) - et al.
Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis
J Pediatr
(1993) - et al.
A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis
J Pediatr
(1995) - et al.
Dexamethasone in bronchiolitis: a randomised controlled trial
Lancet
(1996) - et al.
Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study
J Pediatr
(1997) - et al.
Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure
J Pediatr
(1996) - et al.
Immunogenicity and pathogenicity of a triple temperature sensitive modified respiratory syncytial virus in adult volunteers
Vaccine
(1993) - et al.
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
J Pediatr
(1998) - et al.
Respiratory syncytial virus immune globulin prevents acute otitis media in high-risk children
J Pediatr
(1996) - et al.
Recovery of cytopathogenic agent from chimpanzees with coryza
Proc Soc Exp Biol Med
(1956)
Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent: I, isolation, properties and characterization
Am J Hyg
The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries
World Health Stat Q
Respiratory virus immunization: I, a field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
Am J Epidemiol
Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children
N Engl J Med
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
Pediatrics
Risk of primary infection and reinfection with respiratory syncytial virus
Am J Dis Child
Age specific prevalence of complement fixing antibodies to sixteen viral antigens: a computer analysis of 58 500 patients covering a period of 8 years
J Med Virol
Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults
J Infect Dis
Respiratory syncytial virus and influenza A infections in the hospitalized elderly
J Infect Dis
The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries
Rev Infect Dis
Respiratory syncytial virus infection in tropical and developing countries
Trop Med Int Health
Bronchiolitis in tropical south India
Am J Dis Child
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
Proc Natl Acad Sci USA
Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections
J Med Virol
Role of T- lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice
J Clin Invest
Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
Am J Respir Crit Care Med
Cited by (475)
Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: A systematic analysis of the Global Burden of Disease 2019 Study
2023, International Journal of Infectious DiseasesLong-acting vaccine delivery systems
2023, Advanced Drug Delivery ReviewsOutbreak of respiratory syncytial virus subtype ON1 among children during COVID-19 pandemic in Southern Taiwan
2022, Journal of Microbiology, Immunology and InfectionNew strategies for the prevention of respiratory syncytial virus (RSV)
2022, Early Human Development